Millennium reported a 5.20 percent stake while Maravai LifeSciences stock traded at EUR 6.58

Published on 10/08/2026 at 12:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue was USD 51.44 million, 5.69 percent above consensus. Maravai LifeSciences stock costs EUR 6.58 on October 8, 2026 versus EUR 6.63.

MRVI, US56600D1072, Illustration mit AI erstellt.

Maravai LifeSciences (ISIN US56600D1072) stock was trading at EUR 6.58 at Lang & Schwarz on October 8, 2026 at 12:30 p.m. CEST, minus 0.75 percent versus the prior close of EUR 6.63. Millennium reported a 5.20 percent stake in the company after a September 22, 2026 filing event, according to StockTitan.

Millennium discloses 7.77 million shares

The Schedule 13G covered 7,773,149 Class A shares, equal to 5.20 percent of the class. Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander each reported shared voting and dispositive power over that block, while sole voting and dispositive power stood at zero, the filing summary said.

The disclosure is an ownership data point rather than an operating update. It gives Maravai a visible institutional holder with shared control rights, but the filing itself says the disclosure is not an admission of beneficial ownership.

Revenue beat the second-quarter consensus

Maravai reported USD 51.44 million of revenue in the second quarter of 2026, compared with USD 48.67 million expected by analysts, according to MarketBeat. The 5.69 percent revenue comparison provides the clearest quantified operating signal in the latest reported quarter.

Yahoo Finance reported adjusted EBITDA of USD 8.70 million in the second quarter, versus a negative USD 10.40 million a year earlier. The same report said adjusted EBITDA guidance for fiscal 2026 was USD 33.00 million to USD 35.00 million, up from USD 30.00 million to USD 32.00 million, while USD 14.30 million of first-quarter CleanCap orders were tied to COVID vaccine programs.

Stock remains below its yearly high

Maravai operates in biotechnology and supplies nucleic-acid products, enzymes and impurity-testing products used in vaccine, therapy and diagnostic development. Its latest market capitalization was USD 2.1 billion as of October 7, 2026, while the 52-week range was USD 1.95 to USD 9.42.

The latest figures leave two competing readings. Revenue exceeded the second-quarter consensus, and adjusted EBITDA guidance improved, but the CleanCap order disclosure shows that part of the growth comparison included a one-off demand component. The filing and operating data therefore point to institutional interest alongside a still developing earnings recovery.

MRVI trades at EUR 6.58

MRVI was trading at EUR 6.58 at Lang & Schwarz on October 8, 2026 at 12:30 p.m. CEST, minus 0.75 percent versus the prior close of EUR 6.63 on October 7, 2026. The primary listing is Nasdaq, where the quotation currency is USD.

The further course of trading is shown by the continuously updated real-time quote of Maravai LifeSciences stock.